Do fever-relieving medicines have anti-COVID activity: an *in silico* insight

Fahad Hassan Shah1, Kyeong Ho Lim2 & Song Ja Kim*,1
1Department of Biological Sciences, College of Natural Sciences, Kongju National University, Gongju 32588, Republic of Korea
2Department of Construction and Environmental Engineering, College of Engineering, Kongju National University, Cheonan 31080, Republic of Korea
*Author for correspondence: ksj85@kongju.ac.kr

Aim: The present study was performed to determine the inhibitory interaction of fever-relieving medicines with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) essential proteins. Materials & methods: Structure-based drug repositioning was performed using PYRX 0.9 and these drugs were directed toward the predicted active site of SARS-CoV-2 spike glycoprotein receptor-binding domain, main protease and RNA-dependent RNA polymerase. Results: Results showed that acetaminophen and naproxen have considerable inhibitory activity and show a high affinity for active residues of these proteins. The prediction of activity spectra for substances (PASS) studies showed that these drugs are anti-inflammatory, antiviral and immunostimulant. Conclusion: Hence, it is proven that these drugs have antiviral activity against SARS-CoV-2 and can stimulate the immune and anti-inflammatory response against this disease.

First draft submitted: 3 December 2020; Accepted for publication: 9 March 2021; Published online: 24 March 2021

Keywords: acetaminophen • antiviral activity • drug repositioning • naproxen • nonsteroidal anti-inflammatory drugs • novel coronavirus-19 • prediction of activity spectra for substances
medicines, whereas other patients require extra supportive care to eradicate this infection [5]. So, it was hypothesized that fever medicines not only tackle fever but also perform antiviral activity by improving the immune response and inhibiting SARS-CoV-2 replication [6]. To elucidate this unexplained biological activity of fever medicine, the current research study was designed to determine the anti-Covid activity of fever-relieving medicines using an in silico screening platform.

### Materials & methods

#### Receptors & ligands preparation

Critical SARS-CoV-2 proteins responsible for replication (SARS-CoV-2 RNA-dependent RNA polymerase (PDB ID: 6M71), viral–host interaction (SARS-CoV-2 receptor-binding domain (PDB ID: 7JMO) and viral polyprotein processing (SARS-CoV-2 main protease (PDB ID: 6LU7) were selected and procured from the RCSB protein databank (Supplementary Table 1). These protein receptors were initially prepared by removing pre-existing ligands and water ions from them through the Discovery Studio program and then minimized with Modrefiner [7]. Fever-alleviating drugs listed in (Table 1) were obtained from PubChem and refined with the PRODRG Server [8].

#### Active site prediction

In order to predict the probable inhibitory interaction of ligands with corresponding receptors, active site residues play an integral role in substrate processing and inhibition of protein function. The interaction of ligands with these active residues halt substrate processing, which results in protein inhibition. By keeping this strategy in mind, DogSite Scorer [9] and Prank Web [10] were used to predict the active site residues within these receptors to direct these ligands toward these areas in the screening analysis.

#### Drug repositioning procedure

Both minimized and refined versions of receptors and ligands were loaded on PYRX 0.9 software to facilitate the interaction of these drugs with the predicted active site residues of SARS-CoV-2 receptors (Supplementary Table 2). The algorithm selected for docking interaction between receptor-ligands was Autodock 4.2, which provides highly accurate results resembling in vitro results.

#### PASS analysis & compound pharmacokinetics

Screened ligands SMILES (Supplementary Table 3) was used to predict important biological activities using the prediction of activity spectra for substances database (PASS) [11]. The pharmacokinetic prediction was performed to evaluate the efficacy and absorption, distribution, metabolism, excretion and toxicity (ADMET) qualities of these ligands through ADMET SAR 2.0 [12] and pKCSM [13].

### Results

#### Drug repurposing results

Structure-based drug repositioning was performed that uses docking algorithm to target ligands toward a directed area for interaction on the receptor. The selected ligands, (Table 1) were focused on the active interface of SARS-CoV-2 receptors. These receptors were spike glycoprotein receptor binding domain (RBD), main proteases (M\(^{\text{PRO}}\)) and RNA-dependent RNA polymerase (RdRp) enzyme implicated in the processing of viral polyproteins, virus–host interaction and viral replication. Among seven widely exploited fever-relieving drugs, acetaminophen and

| N | DRUGS               | Pubchem CID |
|---|---------------------|-------------|
| 1 | Acetaminophen       | 1983        |
| 2 | Acetylsalicylic acid| 2244        |
| 3 | Ibuprofen           | 3672        |
| 4 | Mefenamic acid      | 4044        |
| 5 | Nimesulide          | 4495        |
| 6 | Naproxen            | 156391      |
| 7 | Diclofenac Sodium   | 5018304     |
| 8 | Piroxicam           | 54676228    |
**Table 2. Docking interaction of ligands with SARS-CoV-2 receptors.**

| N | Receptors | Ligands | Active site subunits predicted by DoGSiteScorer and Prank Web | Chemical bonding between receptor and ligands | Functional groups participating in hydrogen bond formation | Binding energy (Kcal/mol) | Ligand efficiency (Kcal/mol) | Inhibition constant (Ki) | LigRMSD calculation (Å) |
|---|-----------|---------|---------------------------------------------------------------|-------------------------------------------------|----------------------------------------------------------|--------------------------|----------------------------|---------------------------|--------------------------|
| 1 | SARS-CoV-2 main protease (6LU7) | Acetaminophen (Pubchem CID: 1983) | HIS41, MET49, PHE140, GLY143, CYS145, HIS164, GLU166, LEU167, PRO168, GLN189, THR190, ALA191 | MET165, GLU166, VAL186 | Hydroxyl and amide groups | -4.5 | 0.40 | 487.06 μM | 1.87 |
|   | Naproxen (Pubchem CID: 156391) | | | | GLY143, SER144, CYS145 | Carboxylic group | -6.1 | 0.35 | 256.76 μM | 1.44 |
| 2 | SARS-CoV-2 receptor binding domain (7JMO) | Acetaminophen (Pubchem CID: 1983) | LEU273, GLY274, GLN275, GLY276, CYS277, PHE 278, GLY279, VAL281, Ala293, LYS295, LEU297, MET302, PHE307, MET314, VAL323, LEU325, ILE336, THR338, TYR340, MET341, SER342, GLY344, SER345, ASP348, ASP386, ARG388, ALA390, ASN391, LEU393, ALA403, ASP404, GLY405, LEU407, ALA408, ILE411, TYR416, LYS423, PRO425 | PHE338, GLY339, LEU368 | Hydroxy and amide groups | -5.7 | 0.51 | 109.51 μM | 2.64 |
|   | Naproxen (Pubchem CID: 156391) | | | | CYS336, PHE338, ASP364 | Carboxylic group | -6.2 | 0.36 | 104.87 μM | 2.21 |
| 3 | SARS-CoV-2 RNA-dependent RNA polymerase (6M71) | Acetaminophen (Pubchem CID: 1983) | LYS47, TYR129, HIS133, ASP135, ASN138, ASN705, SER709, THR710, GLY774, LYS780, ASN781, SER784 | PHE45, HIS133, ASN705 | Hydroxy and Amide group | -6.1 | 0.55 | 134.97 μM | 3.11 |
|   | Naproxen (Pubchem CID: 156391) | | | | GLN468, ASN705 | Carboxylic Group | -6.2 | 0.37 | 76.89 μM | 2.89 |

**Figure 1.** Binding pattern and functional groups exploited by acetaminophen to interact with SARS-CoV-2 main protease.

Naproxen had favorable hydrogen bonding with the targeted active site of these receptors with binding energy of \(~4.5\text{--}6.2\text{ kcal/mol}\), as shown in (Table 2).

**SARS-CoV-2 main protease (M\textit{PRO})**

Hydroxyl and amide group of acetaminophen formed hydrogen bonds with MET165, GLU166 and VAL186 (Figure 1), whereas MET165 and GLN189 participated in hydrophobic interactions with the benzene group. The carboxylic group of naproxen established interactions with GLY143, SER144 and CYS145, and hydrophobic interaction made by the benzene group with CYS145, and MET165 (Supplementary Figure 1).
Table 3. Lethal dosage of ligands and its corresponding adverse and organ damaging effects.

| N | Compounds                  | LD50 value for intraperitoneal route (mg/kg) | LD50 value for intravenous route (mg/kg) | LD50 value for oral route (mg/kg) | LD50 value for subcutaneous route (mg/kg) | Chemical classification by OECD project | Adverse effects                                      | Organ-specific damage                        |
|---|----------------------------|---------------------------------------------|------------------------------------------|----------------------------------|------------------------------------------|------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| 1 | Acetaminophen (Pubchem CID: 1983) | 714,200                                     | 100,400                                  | 2,629,000                       | 1,132,000                                | Class 5                                  | Nephrotoxicity, myocardial infarction, cardiac failure | Urinary bladder, kidney, stomach, hematopoietic system, thyroid gland and ovaries |
| 2 | Naproxen (Pubchem CID: 156391) | 502,900                                     | 233,500                                  | 907,100                          | 606,000                                  | Class 4                                  | Hepatotoxicity, myocardial infarction, cardiac failure, nephrotoxicity | Skin, urinary bladder and kidney              |

**SARS-CoV-2 spike glycoprotein (RBD)**

Acetaminophen established three hydrogen bonds with PHE338, GLY339 and LEU368 whereas benzene ring participated in forming hydrophobic interactions with PHE338 and VAL367 (Supplementary Figure 2). Naproxen employed carboxylic group to form hydrogen bonds with CYS336, PHE338 and ASP364 and benzene rings and oxy-group established hydrophobic interactions with VAL367, PHE338, LEU368 and PHE374 (Supplementary Figure 3).

**SARS-CoV-2 RNA polymerase enzyme (RdRp)**

Three hydrogen interactions were formed by three separate functional groups (hydroxyl, amino and carboxyl) of acetaminophen with PHE45, HIS133 and ASN705. Naproxen exploited the carboxylic group to form two hydrogen bonds with GLN468 and ASN705 and benzene rings and oxy-group formed hydrophobic interactions with PHE45, LEU708, TYR129 and ALA34, respectively (Supplementary Figures 4 & 5).

**Ligands toxicity behavior**

The toxic behavior of acetaminophen and naproxen was determined in rodent models by administering various doses through four administration routes. It was observed that acetaminophen incites adverse and organ-damaging effects, when the quantity of the drug is increased to 2,000,000 mg/kg orally, 100,000 mg/kg intravenously and 700,000 mg/kg and 1,100,000 mg/kg for the intraperitoneal and subcutaneous route. For naproxen, acute toxicity recorded for intraperitoneal route was 500,000 mg/kg; 200,000 mg/kg for intravenous route; 900,000 mg/kg oral; and 600,000 mg/kg for subcutaneous. OECD chemical classification results placed acetaminophen in Class 5 chemicals and naproxen in Class 4, respectively. The organ-damaging effects (Supplementary Table 4) and adverse effects of these drugs are summarized in (Table 3).

**PASS & pharmacokinetic prediction of ligands**

The activity of acetaminophen and naproxen was analyzed with thousands of biologically active substrates to discover new effects and mechanisms, which was facilitated by PASS online server. The biological activities predicted by PASS algorithm are 90 % synonymous with *in vitro* experiments [11]. Results showed that acetaminophen is an antiviral agent, active against influenza, picornavirus, adenovirus, coronavirus, HIV and herpes virus. This provides invaluable justification that acetaminophen is involved in subduing viral proliferation activity. Also, they are immunostimulant and inhibit the activity of transcription factor NF-κB. Naproxen is active against rhinoviruses, picornaviruses and influenza and dampens the response of NF-κB and IL-6, which are implicated in the cytokine storm (Table 4).

Both of these drugs have high intestinal absorption equipped with increased blood–brain barrier (BBB) penetration capability and oral bioavailability, except for acetaminophen, which lacks oral bioavailability. Subcellular localization of these drugs are mitochondria and are nonreactive toward P-glycoprotein. Acetaminophen possesses affinity for CYP2C9 substrates and naproxen for CYP2C9 and inhibits CYPE1A2. These drugs are noncarcinogenic and nonmutagenic. Naproxen has low water solubility and high plasma protein binding, whereas acetaminophen has high water solubility and low plasma protein-binding affinity (Table 5).
### Table 4. Biological activity of ligands predicted by PASS online.

| N  | Compounds                              | Pa  | Pi      | Biological activity                               |
|----|----------------------------------------|-----|---------|---------------------------------------------------|
| 1  | Acetaminophen (Pubchem CID: 1983)      | 0.588 | 0.014 | Antiviral (Influenza)                             |
|    |                                        | 0.551 | 0.032 | Antiviral (Picornavirus)                          |
|    |                                        | 0.473 | 0.009 | Antiviral (Adenovirus)                            |
|    |                                        | 0.400 | 0.004 | \(^1\)HIV-2 reverse transcriptase inhibitor       |
|    |                                        | 0.342 | 0.009 | \(^3\)C-like protease (Human coronavirus) inhibitor |
|    |                                        | 0.342 | 0.013 | Transcription factor NF kappa B inhibitor         |
|    |                                        | 0.370 | 0.059 | Immunostimulant                                   |
|    |                                        | 0.310 | 0.048 | RNA synthesis inhibitor                           |
|    |                                        | 0.307 | 0.056 | Antiviral (Poxvirus)                              |
|    |                                        | 0.310 | 0.076 | \(^3\)HCV IRES inhibitor                         |
|    |                                        | 0.312 | 0.083 | Antiviral (Herpes)                                |
| 2  | Naproxen (Pubchem CID: 156391)         | 0.870 | 0.005 | Anti-inflamatory                                  |
|    |                                        | 0.860 | 0.003 | Antipyretic                                       |
|    |                                        | 0.642 | 0.006 | Nonsteroidal anti-inflammatory agent              |
|    |                                        | 0.449 | 0.049 | Antiviral (Rhinovirus)                            |
|    |                                        | 0.361 | 0.146 | Antiviral (Picornavirus)                          |
|    |                                        | 0.342 | 0.010 | Interleukin 6 antagonist                          |
|    |                                        | 0.335 | 0.015 | \(^3\)Transcription factor NF kappa B inhibitor  |
|    |                                        | 0.327 | 0.110 | Analgesic                                         |
|    |                                        | 0.313 | 0.081 | Antiviral (Influenza)                             |

\(^1\)C-like protease: 3-Chymotrypsin-like cysteine protease; HCV IRES: Hepatitis C virus Internal Ribosome Entry Site; HIV: Human immunodeficiency virus; NF kappa B: Nuclear Factor Kappa B.

### Discussion

Asymptomatic disease nature, uncontrollable inflammatory response and delayed immunological reactions are typical manifestations of novel coronavirus infection. These manifestations are caused by nonstructural proteins processed by SARS-CoV-2 main proteases [3], whereas replication and virus–cell interactions are facilitated by RdRp and spike protein [1,14]. Currently, these targets are being exploited for vaccine and drug design and development studies. Several different drug candidates have been introduced from various screening, in vitro and clinical studies in the past few months. Drugs approved by the US FDA for the treatment of novel coronavirus in critical patients are remdesivir and baricitinib [15]. However, their dosages must be calibrated for an effective response against this virus and prevent deleterious side effects. The mild symptomatic cases are dealt with fever relieving medicines to alleviate fever and other symptoms to buy enough time for the host body to develop an immune response to ward off this infection. Interestingly, 80% of patients recover from this disease by taking these fever relieving medicines [5]. Being analgesic, anti-inflammatory and antipyretic agent, these drugs are somehow acting as an antiviral agent in this disease, which remained elusive until now. To unravel this mystery, we have performed a drug repositioning study to check the inhibitory interaction of these fever-relieving medicines against SARS-CoV-2 essential proteins. It was observed that only two commonly exploited drugs (acetaminophen and naproxen) successfully established hydrogen interaction with the active site residues of these receptors with adequate binding energy, and ligand efficiency. Furthermore, root-mean-square deviation (RMSD) and inhibitory constant values favored these drugs. PASS prediction studies revealed that acetaminophen has moderate antiviral activity against different viruses including coronaviruses and low immunostimulant activity. On the other hand, naproxen has strong anti-inflammatory activity and avert the proliferation of rhinoviruses, picornaviruses and influenza viruses and inhibit NF-κB and IL-6 activity.

These activities suggest that, in the early phase of SARS-CoV-2 infection, these drugs will perform antiviral activity by reducing viral entry by binding to the RBD of spike glycoprotein, modulate adaptive immune response and ameliorate viral clearance by dampening the viral polyprotein processing and replication. These drugs will also prevent SARS-CoV-2-induced damage to pulmonary epithelial cells and other organs implicated in the pulmonary phase. Our findings are in consonance with Terrier et al., 2020 [16] preprint, who infected Vero E6 cell and 3D reconstituted human airway epithelia with SARS-CoV-2 to evaluate the antiviral and pulmonary protective...
Table 5. Pharmacokinetic analysis of screened ligands.

| Properties                           | Acetaminophen (Pubchem CID: 1983) | Naproxen (Pubchem CID: 156391) |
|--------------------------------------|-----------------------------------|---------------------------------|
| **Absorption**                       |                                   |                                 |
| Human intestinal absorption          | High +                            | High +                          |
| \(^1\)Caco-2                         | +                                 | +                               |
| Water solubility (log mol/l)         | -1.131 (soluble)                  | -4.098 (highly soluble)         |
| Plasma protein binding               | 0.372                             | 1.052                           |
| **Distribution**                     |                                   |                                 |
| P-glycoprotein substrate             | -                                 | -                               |
| P-glycoprotein I inhibitor           | -                                 | -                               |
| P-glycoprotein II inhibitor          | -                                 | -                               |
| \(^1\)BBB permeability              | +                                 | +                               |
| Oral bioavailability                | -                                 | +                               |
| Sub-cellular localization            | Mitochondria                      | Mitochondria                    |
| **Metabolism**                       |                                   |                                 |
| \(^1\)CYP3A4 substrate               | -                                 | -                               |
| CYP2C9 substrate                     | +                                 | +                               |
| CYP2D6 substrate                     | -                                 | -                               |
| CYP3A4 inhibition                    | -                                 | -                               |
| CYP2C9 inhibition                    | -                                 | -                               |
| CYP2C19 inhibition                   | -                                 | -                               |
| CYP2D6 inhibition                    | -                                 | -                               |
| CYP1A2 inhibition                    | -                                 | +                               |
| **Excretion**                        |                                   |                                 |
| Total clearance (log ml/min/kg)      | 0.493                             | 0.193                           |
| Renal OCT2 substrate                 | No                                | No                              |
| **Toxicity**                         |                                   |                                 |
| \(^1\)AMES toxicity                 | No                                | No                              |
| Hepatotoxicity                       | No                                | No                              |
| \(^1\)hERG inhibition                | No                                | No                              |
| Eye irritation                       | No                                | No                              |
| Carcinogenicity                      | No                                | No                              |

\(^1\)AMES: Salmonella typhimurium reverse mutation assay; BBB: Blood–brain barrier; Caco-2: Colorectal adenocarcinoma cells; CYP: Cytochromes P450; hERG: human ether-a-go-go related gene; OCT: Organic cation transporter 2.

In their study, naproxen dose-dependently reduced viral titers in both cell lines and induced a protective effect against viral-induced damage. Naproxen also reduces IL-6 and NF-kB levels as evident from the study by Kang et al., 2001 [17], which can be useful in reducing cytokine storm and organ damage during hyper-inflammation phase. However, these results are specific for naproxen, whereas the role of acetaminophen remains elusive in this disease, but can be explored by employing various in vitro experiments to confirm these in silico predicted activities.

Toxicity and pharmacokinetic studies were performed to evaluate the toxicity and pharmacokinetic properties of these drugs, to equip scientists with valuable information about these drugs that will help them devise various approaches to amplify its antiviral and anti-inflammatory response in animal and clinical trials. Acetaminophen has high acute toxicity values with mild adverse effects but possesses low oral bioavailability. Naproxen has comparatively low acute toxicity than acetaminophen, with life-threatening side effects. Both toxic and bioavailability issues can be resolved with controlled drug-release properties [18], drug-delivery nanocarriers [19] and drug-dose calibration [20].

**Conclusion**

To the best of our knowledge, our study predicted the antiviral mechanism of acetaminophen and naproxen for the first time. These drugs are highly effective against essential SARS-CoV-2 protein targets and possess moderate activity of naproxen. In their study, naproxen dose-dependently reduced viral titers in both cell lines and induced a protective effect against viral-induced damage. Naproxen also reduces IL-6 and NF-kB levels as evident from the study by Kang et al., 2001 [17], which can be useful in reducing cytokine storm and organ damage during hyper-inflammation phase. However, these results are specific for naproxen, whereas the role of acetaminophen remains elusive in this disease, but can be explored by employing various in vitro experiments to confirm these in silico predicted activities.

Toxicity and pharmacokinetic studies were performed to evaluate the toxicity and pharmacokinetic properties of these drugs, to equip scientists with valuable information about these drugs that will help them devise various approaches to amplify its antiviral and anti-inflammatory response in animal and clinical trials. Acetaminophen has high acute toxicity values with mild adverse effects but possesses low oral bioavailability. Naproxen has comparatively low acute toxicity than acetaminophen, with life-threatening side effects. Both toxic and bioavailability issues can be resolved with controlled drug-release properties [18], drug-delivery nanocarriers [19] and drug-dose calibration [20].

**Conclusion**

To the best of our knowledge, our study predicted the antiviral mechanism of acetaminophen and naproxen for the first time. These drugs are highly effective against essential SARS-CoV-2 protein targets and possess moderate
Fever-relieving medicines against COVID-19

Research Article

Toxicity and pharmacokinetic properties. However, more studies are essential to validate the findings of this research in animals and clinical trials. The findings of this study have opened a new and safer gateway for using these drugs as a prophylactic and antiviral medication that can be of great significance to clinicians and biomedical scientists struggling to curb the ongoing pandemic.

Summary Points

- SARS-CoV-2, also known as novel coronavirus-19 (COVID-19) is a highly contagious and life-threatening disease and employs spike glycoprotein, main proteases and RNA-dependent RNA polymerase enzyme to interact with angiotensin-converting enzyme-2 receptors on host cells, process viral polyproteins and replicate to produce viral copies of themselves inside the infected cell.
- Most patients infected with this virus recover and develop immunity against this disease by taking fever relieving medicines and supportive care.
- Structure-based drug repositioning studies confirmed that acetaminophen and naproxen act as antiviral, anti-inflammatory and immunostimulatory agents against this disease.
- These drugs interact with active ligand binding site residues of spike glycoprotein, main protease and RdRp enzyme.
- Further biological activities predicted by PASS indicate that these drugs are active against coronavirus and various other pathogenic viruses and can prevent the onset of cytokine storm.
- Toxicity and pharmacokinetic properties of these drugs are cautionary but can be ameliorated with drug delivery, controlled drug release and drug dose calibration methods.
- To the best of our knowledge, this study is the first of its kind to describe the antiviral activity of acetaminophen and naproxen against essential SARS-CoV-2 receptors.

Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fvl-2020-0398

Author contributions
All authors equally contributed for this study.

Financial & competing interests disclosure
This work was supported by the National Research Foundation of Korea (NRF) funded by the Korean Government (MEST) (2020R1I1A3069699). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References
Papers of special note have been highlighted as: • of interest; •• of considerable interest

1. Salman S, Shah FH, Idrees J, Idrees F, Velagala S, Ali J et al. Virtual screening of immunomodulatory medicinal compounds as promising anti-SARS-CoV-2 inhibitors. *Future Virol.* 15(5), 267–275 (2020).

- Reports efficacious immunomodulatory compounds for SARS-CoV-2.

2. Uddin M, Mustafa F, Rizvi TA, Loney T, Al Suwaidi H, Al-Marzouqi AHH et al. SARS-CoV-2/COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions. *Viruses* 12(5), 526–544 (2020).

3. Vann KR, Tencer AH, Kutateladze TG. Inhibition of translation and immune responses by the virulence factor Nsp1 of SARS-CoV-2. *Signal Transduct. Target. Ther.* 5(1), 234 (2020).

4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 395(10229), 1033 (2020).

- Discusses the mechanism of SARS CoV-2 in the development of cytokine storm and immunosuppression.

5. Alexandra Barley E, Coghlan B. Supporting recovery from COVID-19. *Br. J. Nurs.* 29(21), 1272–1276 (2020).

6. Capuano A, Scavone C, Racagni G, Scaglione F. Pharmacology IS of NSAIDs in patients with viral infections, including Covid-19: victims or perpetrators? *Pharmacol. Res.* 157, 104849 (2020).

- Discusses the protective effects of nonsteroidal anti-inflammatory drugs in viral infections.
7. Xu D, Zhang Y. Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization. *Biophys. J.* 101(10), 2525–2534 (2011).
8. Schüttelkopf AW, Van Aalten DMF. PRODRG: a tool for high-throughput crystallography of protein–ligand complexes. *Acta Crystallogr. Sect. D Biol. Crystallogr.* 60(8), 1355–1363 (2004).
9. Fährholffs R, Bietz S, Flachssenberg F et al. Proteins Plus: a web portal for structure analysis of macromolecules. *Nucleic Acids Res.* 45(W1), W337–W343 (2017).
10. Jendele L, Krivak R, Skoda P, Novotny M, Hoksza D. PrankWeb: a web server for ligand binding site prediction and visualization. *Nucleic Acids Res.* 47(W1), W345–W349 (2019).

- A bioinformatic database used to predict potential ligand binding sites in a protein structure.

11. Laganin A, Stepanchikova A, Filimonov D, Poroskov V. PASS: prediction of activity spectra for biologically active substances. *Bioinformatics.* 16(8), 747–748 (2000).

- An online webserver used to predict different biological activities of a compound.

12. Yang H, Lou C, Sun L et al. admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties. *Bioinformatics.* 35(6), 1067–1069 (2019).

- A bioinformatic database used to predict pharmacokinetic and drug likeness properties of a compound.

13. Pires DEV, Blundell TL, Ascher DB. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. *J. Med. Chem.* 58(9), 4066–4072 (2015).

- A bioinformatic database used to predict pharmacokinetic and toxicity properties of a compound.

14. Emirik M. Potential therapeutic effect of turmeric contents against SARS-CoV-2 compared with experimental COVID-19 therapies: in silico study. *J. Biomol. Struct. Dyn.* 1–14 (2020).

- An in silico study describing the role of Turmeric Compounds against SARS-CoV-2 targets.

15. US Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19. www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19

16. Terrier O, Dilly S, Pizzorno MA, Henri J, Berenbaum F, Lina B et al. Broad-spectrum antiviral activity of naproxen: from influenza A to SARS-CoV-2 coronavirus. *bioRxiv* doi:10.1101/2020.04.30.069922 (2020) (Epub ahead of print).

- Describe the antiviral activity of Naproxen against SARS-CoV-2 and Influenza A.

17. Kang BS, Chung EY, Yun YP, Lee MK, Lee YR, Lee KS et al. Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity. *Biol. Pharm. Bull.* 24(6), 701–703 (2001).

18. Park K. Controlled drug delivery systems: past forward and future back. *J. Control. Release* 190, 3–8 (2014).

19. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres del MP, Acosta-Torres LS et al. Nano based drug delivery systems: recent developments and future prospects. *J. Nanobiotechnology* 16(1), 71 (2018).

20. Coulet A, Shah NH, Wack M, Chawki MB, Jay N, Dumontier M. Predicting the need for a reduced drug dose, at first prescription. *Sci. Rep.* 8(1), 15558 (2018).